Maker of dubious $56K Alzheimer’s drug offers cognitive test no one can pass
Ars Technica » Scientific Method 2021-07-23
Summary:
After facing intense criticism, Biogen goes on defense, blames "misinformation."
Link:
https://arstechnica.com/?p=1782649From feeds:
Cyberlaw » Ars TechnicaMusic and Digital Media » Ars Technica
Berkeley Law Library -- Reference & Research Services » Ars Technica » Scientific Method